Business
Optimer licensing agreements and repeat contracts
Optimer licensing agreements and repeat contracts.
About this update from Aptamer Group Plc
[{"type":"text","content":"\n\n \n15 May 2025\n \nAptamer Group plc\n \n(\"Aptamer\", the \"Company\" or the \"Group\")\n \nOptimer licensing agreements and repeat contracts\nLicensing with global enzyme provider for two Optimer reagents in research and diagnostics\nRepeat development contracts worth up to £231,000 signal continued commercial traction\n \nAptamer Group plc (AIM: APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, is pleased to announce two new fee-for-service development contracts with existing customers, with a combined value of up to £231,000, demonstrating continued confidence in the Optimer platform. The Group has also agreed licensing heads of terms with a global provider of speciality enzymes for developed enzyme-modulating Optimers.\n \nThe first of the two new development contracts, valued at up to £105,000, focuses on creating additional enzyme-modulating Optimers to broaden the customer's reagent offering. This is the second project with this customer. The second development contract is with a top 20 global pharmaceutical company. Valued at up to £126,000, this new fee-for-service development project will involve the development of Optimer reagents targeting a small molecule for use in the customer's internal research programmes. This marks a second project with the pharmaceutical customer, following a previously successful Optimer development and represents further repeat business. Aptamer will retain IP rights on the binders, with potential for future downstream licensing revenue.\n \nThe licensing terms with the global enzyme provider cover Optimer binders developed under two separate fee-for-service contracts. The binders for the first contract were successfully delivered in January 2025 and demonstrated excellent performance both at Aptamer and in the customer's in-house tests, leading to the additional fee-for-service work. The agreed licensing terms for this contract include undisclosed milestone payments and a 10% royalty on sales of all Optimer-containing products. Initial revenues from this non-exclusive arrangement are expected within the financial year ended June 2026, representing one additional licensing opportunity to the ten opportunities outlined in the interim results in March 2025. Licensing terms on the s...